

Noevir Holdings Co., Ltd. Results for the First Half of Fiscal 2025

(October 1, 2024 – March 31, 2025)

May 15, 2025
Noevir Holdings Co., Ltd.
Ikkou Yoshida, Managing Director

Company Overview



Noevir Holdings Co., Ltd. Tokyo Stock Exchange, Prime Market Ticker: 4928

Date of Establishment March 22, 2011 (Noevir Co., Ltd. was founded in April 1964.)

Paid-in Capital ¥7,319 million

Consolidated Subsidiaries 13 subsidiaries (6 domestic / 7 international)

Employees 1,369 (Consolidated) (As of September 30, 2024)

Number of Shareholders 22,943 (As of March 31, 2025)

Outstanding Shares 34,156 thousand shares

Market Capitalization ¥145.507 billion (As of May 14, 2025 @ ¥4,260)

Line of Business





Pharmaceuticals & Health Food

Apparel business Aviation-related business

Other



- 1. Results for the First Half of Fiscal 2025
- 2. The First Half of Fiscal 2025
 Segment-Based Highlights
- 3. Medium- to Long-term Strategy
- 4. Forecasts and Initiatives for the Second Half of Fiscal 2025



Increased sales, decreased operating income, and increased net income vs. actual results year on year

	1st half of fiscal 2025	Year-on-year change
Net sales	32.0 billion yen	1.3%
Operating income	5.7 billion yen	(7.3%)
Net income attributable to owners of the parent	2.6 billion yen	1.7%
Operating income margin	17.8%	(1.7pt)


- ➤ Factors increasing sales and decreasing profits (Factors increasing net income)
 - 1) Functional drinks performed strongly Face-to-face channel cosmetics performed firmly
 - ②Product mix changes
 - 3 Increased marketing costs

Operating income margin 17.8%

Net sales 32.0 billion yen (+1.3% year-on-year), operating income 5.7 billion yen (-7.3%), ordinary income 6.0 billion yen (-3.5%), net income attributable to owners of the parent 2.6 billion yen (+1.7%)

	1st half ended March 31, 2025	1st half ended March 31, 2024	Year-on-year change	
	Millions of yen	Millions of yen	Millions of yen	%
Net sales	32,037	31,625	411	1.3
Cost of sales	10,414	9,935	478	4.8
Gross profit	21,622	21,689	(67)	(0.3)
SG&A	15,910	15,524	386	2.5
Operating income	5,712	6,165	(453)	(7.3)
Non-operating income (expenses)	313	80	232	286.9
Ordinary income	6,025	6,246	(221)	(3.5)
Extraordinary income (loss)	87	13	74	539.2
Income before income taxes	6,112	6,259	(146)	(2.3)
Income taxes	3,471	3,661	(190)	(5.2)
Net income attributable to owners of the parent	2,641	2,597	43	1.7
Cost of sales ratio (%)	32.5	31.4	_	1.1pt
Operating income margin (%)	17.8	19.5	_	(1.7pt)
Ordinary income margin (%)	18.8	19.8	_	(0.9pt)
Net income attributable to owners of the parent margin (%)	8.2	8.2	-	0.0pt
SG&A ratio (%)	49.7	49.1	_	0.6pt






Continued to maintain a high operating income margin in 1H FY2025






Factors decreasing profit









- 1. Results for the First Half of Fiscal 2025
 - 2. The First Half of Fiscal 2025 Segment-Based Highlights
- 3. Medium- to Long-term Strategy
- 4. Forecasts and Initiatives for the Second Half of Fiscal 2025

Sales and profits

decreased year on year

Other




	1st half ended March 31, 2025	1st half ended March 31, 2024	Year-on-ye	ear change	
	Millions of yen	Millions of yen	Millions of yen	%	Other
Cosmetics					Pharmaceuticals & 3.1% Health Food
Net sales	25,442	25,103	339	1.4	1750
Segment income	6,413	6,507	(93)	(1.4)	17.5%
Pharmaceuticals & Health Food					Net sales 32,037
Net sales	5,596	5,498	98	1.8	million yen
Segment income	425	683	3 (258)	(37.8)	
Other					Cosmetics
Net sales	998	1,024	(25)	(2.5)	79.4%
Segment income	101	150	(48)	(32.3)	73.4%
Consolidated net sales	32,037	31,625	5 411	1.3	Composition of net sales in the first half of fiscal 2025
Cosmetics	Sales increase profits decreas year on year	od	While face-to-face channel cosmetics saw higher sales, profit declined due to decreased sales of self-selection cosmetics and increased marketing costs		
Pharmaceuticals & Health Food	Sales increase profits decreas year on year		Sales of functional drinks increased, but profit decreased due to lower sales of nutritional supplements		

performed firmly

Profit decreased due to lower sales in aircraft-related businesses, while apparel



	1st half ended March 31, 2025	1st half ended March 31, 2024	Year-on-year change	
	Millions of yen	Millions of yen	Millions of yen	%
Net sales	25,442	25,103	339	1.4
Segment income	6,413	6,507	(93)	(1.4)



Composition of net sales in the first half of fiscal 2025

Face-to-face channel cosmetics

- > New beauty serum products SPECIALE x NEWROGIC serum and SILKY LIFT contributed to sales
- > Skincare sales increased overall, driven by the firm performance of SPECIALE skincare line

NOEVIR



SPECIALE skincare line Lotion 200 mL 41,800 yen Cream 50 g 110,000 yen



SPECIALE x NEWROGIC serum 50 g 66,000 yen Newly launched in January 2025



SILKY LIFT 45 g 30,800 yen Newly launched in November 2024



80 skincare line
Total of eight products 1,870 – 3,520 yen
Revamped products went
on sale October 2024

*All prices include tax.



Nameraka Honpo skincare brand

Strove to capture demand through new product launches and sales channel expansion





Wrinkle Brightening Mist Skin Lotion Wrinkle Brightening Essence In-store promotions



3 Types of Eye Cream In-store promotions



Skincare Set
7-Day Supply
Cleansing wash • Lotion • Emulsion



> excel brand

Launched new products tailored to trends and need





In-store promotions















> Pore Putty and New Born makeup brands

Strong performance due to the launch of new products





Pore Putty makeup brand

Pore-concealing base makeup

Pore Less Cushion Foundation Booster Primer
Pore Less Cushion Foundation
Newly launched in September 2024

New Born makeup brand

Multiple functions in one product

Perfect Eyebrow MV
Revamped product went on sale August 2024



> NOV brand

Mainstay product lines performed firmly

NOV



NOV Ⅲ skincare line (Skincare for those concerned about sensitive and dry skin)



NOV L&W skincare line (Highly moisturizing aging care for sensitive skin)



Enhanced and expanded hair care products (Gentle for not only hair but also scalp)

Overseas and OEM business sales


Sales increased in both overseas and OEM



Pharmaceuticals & Health Food

	1st half ended March 31, 2025	1st half ended March 31, 2024	Year-on-year change	
	Millions of yen	Millions of yen	Millions of yen	%
Net sales	5,596	5,498	98	1.8
Segment income	425	683	(258)	(37.8)


- > Sales increased due to strong sales of functional drinks
- > Profit decreased due to lower sales in nutritional supplements



Other

	1st half ended March 31, 2025	1st half ended March 31, 2024	Year-on-year change	
	Millions of yen	Millions of yen	Millions of yen	%
Net sales	998	1,024	(25)	(2.5)
Segment income	101	150	(48)	(32.3)

➤ Profit decreased due to lower sales in aircraft-related businesses, while apparel performed firmly





(Millions of yen)

		As of March 31, 2025	Previous year As of March 31, 2024	Change
Current assets		45,259	48,400	(3,141)
	Cash and cash equivalents	23,799	27,212	(3,412)
	Notes and accounts receivable	10,724	10,512	211
Non-current asse	ts	27,442	26,703	739
	Property, plant and equipment	21,108	20,104	1,003
	Intangible assets	1,196	972	224
	Investments and other assets	5,137	5,626	(488)
	Investment securities	2,841	3,150	(309)
Total assets		72,702	75,104	(2,402)
Current liabilities		11,154	12,827	(1,673)
Long-term liabiliti	es	12,688	13,485	(796)
	Guarantee deposits received	10,956	11,371	(414)
Total liabilities		23,842	26,312	(2,470)
	Shareholder's equity	46,041	45,713	327
	Common stock	7,319	7,319	_
	Retained earnings	38,724	38,396	328
Total net assets		48,859	48,791	67
Total liabilities an	d net assets	72,702	75,104	(2,402)
Equity ratio		66.5%	64.3%	2.2pt



- 1. Results for the First Half of Fiscal 2025
 - 2. The First Half of Fiscal 2025 Segment-Based Highlights
- 3. Medium- to Long-term Strategy
- 4. Forecasts and Initiatives for the Second Half of Fiscal 2025



Having positioned net sales, operating income and return on equity (ROE) as key management indicators, the Noevir Group aims to maximize its corporate value and enhance profitability.

Concept

Five Policies

Realizing steady corporate growth by securing sustainability in every Group business segment

- Pursue innovation and continuous profit generation in the domestic market
- Enhance our brand value
- Some structure of the structure of th
- Strengthen our competitiveness by stepping up the diversification of our R&D, production and logistics systems
- Promote a management approach that is responsive to changes in the business environment



- 1. Results for the First Half of Fiscal 2025
 - 2. The First Half of Fiscal 2025 Segment-Based Highlights
- 3. Medium- to Long-term Strategy
 - 4. Forecasts and Initiatives for the Second Half of Fiscal 2025



	Full year forecasts	Year ended September 30, 2024	Year-on-year chang	-year change	
	Millions of yen	Millions of yen	Millions of yen	%	
Net sales	64,000	63,823	177	0.3	
Operating income	11,500	11,423	77	0.7	
Oridinary income	11,700	11,594	106	0.9	
Net income attributable to owners of the parent	8,000	7,970	30	0.4	





Strive for improved profitability as a core business

Face-to-face channel cosmetics

- Strengthened sales capability
- Increased customer contact points

Self-selection cosmetics

Timely presentation of highly competitive products understanding customer's needs

Face-to-face channel cosmetics

Strengthened sales capability Increased customer contact points

NOEVIR Beauty Studio salons

➤ Roll out to about 2,000 stores in regions nationwide







NOEVIR SALON DE SPECIALE stores

> Roll out 10 stores nationwide











Face-to-face channel cosmetics

> RIPOSOME ULTRA A · C · E

Launch new products and focus on expanding sales

NOEVIR

肌は、もっと美化できる。



LIPOSOME ULTRA A·C·E

RIPOSOME ULTRA A · C · E
45 g 30,800yen Newly launched in May 2025



*prices include tax.




Nameraka Honpo skincare brand

Launch new products and focus on expanding sales











Wrinkle Brightening Essence Mask WH
Moisturizing Essence Mask NC
Newly launched in March 2025



> excel brand

Launch new products and focus on expanding sales





In-store promotions



Pore Putty and New Born makeup brands

Launch new products and focus on expanding sales









New Born makeup brand
Multiple functions in one product
Shooting Liquid Eyebrow
Newly launched in February 2025





> NOV brand

Focus on expanding sales of mainstay series

NOV



NOV is a skincare line based on clinical dermatology studies for those who have dry, sensitive or acne-prone skin.



Image



NOV **I** skincare line (Skincare for those concerned about sensitive and dry skin)



NOV L&W skincare line (Highly moisturizing aging care for sensitive skin)



NOV UV EX line (Gently reduces the harmful effect of UV rays on the skin)



Body soap and hair care (Extra-gentle body wash)



➤ Wrinkle Turn and GLASSOON brand Focus on expanding sales of new brands





GLASSOON



Wrinkle Turn Advanced skincare brand A new, next-level skincare line that fulfils the desire for more serious aging care Newly launched in February 2025



GLASSOON brand
A new joint brand for cosmetics and
healthcare products
Newly launched in March 2025



Pharmaceuticals & Health Food



- Launch distinctive new products
- Strengthen orders for OEM

Pharmaceuticals

- Focus on sales expansion
 - · Nanten Nodo Ame cough drop brand
 - Nutrient tonic drinks










Nanten Nodo Ame cough drop brand

Health Food

- > Focus on sales expansion
 - Min Min Da Ha functional drink brand lineup
 - Nutritional supplements







GLASSOON lipobright VC powder







LIVE master **GEKIMI** Oshi-Katsu supplement Oshi-Katsu energy drink



➤ Improve Profitability

Apparel business

Launch new products

NOEVIR



Aircraft-related business

Continue responding carefully






Achieved stable management efficiency

Dividend and Dividend Payout Ratio



Increased dividends for 13 consecutive periods



Continue stable shareholder return by maximizing corporate value and enhancing profitability

^{*} Dividend payout ratio for fiscal 2011 was calculated from the sum of net income attributable to owners of the parent of Noevir Co, Ltd. for Q2 fiscal 2011 and Noevir Holdings Co., Ltd. for fiscal 2011.



[Inquiries] Noevir Holdings Co., Ltd. Public & Investor Relations Tel: +81-3-5568-0305 Fax: +81-3-5568-0441

E-mail: ir@noevirholdings.co.jp WEB: https://www.noevirholdings.co.jp

These materials contain information that constitutes forward-looking statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual results may differ from those in the forward-looking statements due to various factors including changes in material circumstances.